Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Rises By 72.6%

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 86,300 shares, an increase of 72.6% from the October 15th total of 50,000 shares. Currently, 3.2% of the shares of the stock are sold short. Based on an average daily volume of 831,300 shares, the days-to-cover ratio is currently 0.1 days.

BioCardia Stock Up 4.3 %

BioCardia stock opened at $2.40 on Wednesday. BioCardia has a fifty-two week low of $1.96 and a fifty-two week high of $23.25. The firm’s fifty day moving average price is $2.60 and its 200-day moving average price is $3.37.

BioCardia (NASDAQ:BCDA) last released its earnings results on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). On average, sell-side analysts expect that BioCardia will post -5.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioCardia in a report on Monday, October 28th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.